Filing Details

Accession Number:
0000899243-16-025570
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-07-22 16:05:33
Reporting Period:
2016-07-20
Filing Date:
2016-07-22
Accepted Time:
2016-07-22 16:05:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1512762 Coherus Biosciences Inc. CHRS Biological Products, (No Disgnostic Substances) (2836) 273615821
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1622139 K. Peter Watler C/O Coherus Biosciences, Inc.
333 Twin Dolphin Drive, Suite 600
Redwood City CA 94065
Chief Technical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2016-07-20 50,000 $2.08 50,000 No 4 M Direct
Common Stock, $0.0001 Par Value Disposition 2016-07-20 50,000 $25.02 0 No 4 S Direct
Common Stock, $0.0001 Par Value Acquisiton 2016-07-20 23,741 $1.42 23,741 No 4 M Indirect By Wife
Common Stock, $0.0001 Par Value Disposition 2016-07-20 23,741 $25.00 0 No 4 S Indirect By Wife
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Indirect By Wife
No 4 S Indirect By Wife
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2016-07-20 50,000 $0.00 50,000 $2.08
Common Stock Stock Option (right to buy) Disposition 2016-07-20 23,741 $0.00 23,741 $1.42
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
92,494 2022-12-13 No 4 M Direct
16,247 2023-11-21 No 4 M Indirect
Footnotes
  1. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person.
  2. The transaction was executed in multiple trades in prices ranging from $25.00 to $25.10, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
  3. The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person's wife.
  4. All shares underlying this option are vested and exercisable as of the date hereof.
  5. A portion of the shares underlying this option are vested and exercisable as of the date hereof. The original vesting schedule is as follows: The underlying shares subject to the option vest and become exercisable in successive, equal monthly installments over four years measured from July 30, 2013, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.